Fluorescence-based rapid measurement of sphingosine-1-phosphate transport activity in erythrocytes

Naoki Kobayashi,*† Masato Otsuka,* Akihito Yamaguchi,§ and Tsuyoshi Nishi¹‡¶

Department of Biochemistry,* Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Osaka 573-0101, Japan; Faculty of Pharmaceutical Science,† Teikyo Heisei University, Nakano-ku, Tokyo 164-8530, Japan; Department of Cell Membrane Biology,‡ Institute of Scientific and Industrial Research, Osaka University, Ibaraki, Osaka 567-0047, Japan; and Faculty of Pharmaceutical Science,** Osaka University, Suita, Osaka 565-0871, Japan

Abstract  Sphingosine-1-phosphate (SIP) is present in the blood plasma and acts as a pivotal intercellular signal transmitter in the immune system by recruiting lymphocytes from the thymus and secondary lymphoid tissues. The plasma SIP concentration is maintained by the supply of SIP from erythrocytes. Previously, we showed that SIP release from erythrocytes is mediated by an ATP-dependent transporter. In this study, we attempted to establish a rapid and reliable method for measuring the SIP transport activity in erythrocytes by using a fluorescent SIP analog, 7-nitro-2,1,3-benzoxadiazol-4-yl (NBD)-labeled SIP. NBD-SIP was released from erythrocytes in a time-dependent manner. The NBD-SIP release was reduced after exposure to glyburide, which is an inhibitor of the SIP transporter in erythrocytes. Moreover, the release of NBD-SIP and SIP from erythrocytes was competitively inhibited by intracellular SIP and NBD-SIP, respectively. These results showed that the erythrocyte SIP transporter export SIP. We optimized the sample-preparation conditions and lipid extraction to increase the sensitivity of the assay. Furthermore, we successfully measured NBD-SIP release without lipid extraction by decreasing the concentration of BSA in the assay buffer to 0.1%. This method will be useful for the high-throughput screening of SIP transporter inhibitors using conventional fluorometers.—Kobayashi, N., M. Otsuka, A. Yamaguchi, and T. Nishi. Fluorescence-based rapid measurement of sphingosine-1-phosphate transport activity in erythrocytes. J. Lipid Res. 2016. 57: 2088–2094.

Supplementary key words  lipid transfer proteins • sphingolipids • lysophospholipid • lipids/extrusion • immunology • transporter • 7-nitro-2,1,3-benzoxadiazol-4-yl

Sphingosine-1-phosphate (SIP) is a lipid mediator present in the blood and lymph (1–4). Plasma SIP recruits lymphocytes from the thymus and secondary lymphoid organs to the circulatory system by activating SIP receptors on lymphocytes (5). Many components of blood, such as erythrocytes, platelets, and neutrophils, express sphingosine kinases and produce SIP (6). Platelets contain large amounts of SIP and release it only when activated by stimuli, such as thrombin, whereas erythrocytes constitutively release SIP in the absence of stimuli. Because erythrocytes constitute a large proportion of the blood cells in the body and because they lack SIP-degrading activity catalyzed by SIP lyase (SGPL1), SIP phosphatases (SGPP1 and SGPP2), and phospholipid phosphatases (PLPP1, PLPP2, and PLPP3) (7), they contribute substantially to plasma SIP. In addition to blood cells, endothelial cells constitutively release SIP into the blood without stimuli (8). Thus, plasma SIP is derived mainly from erythrocytes and endothelial cells (9). When the SIP supply from erythrocytes has been disrupted, the plasma SIP level and the number of the lymphocytes in the blood decrease substantially (10). Therefore, plasma SIP supplied by erythrocytes is essential for the correct distribution of lymphocytes in the blood.

Erythrocytes transport sphingosine, which is supplied by other cells, to the intracellular side of the membrane and produce SIP by phosphorylation (6, 7, 11). In addition to the extracellular source of sphingosine, intracellular alka
dine ceramidase also produces sphingosine used for SIP synthesis in human erythrocytes (12). Previously, we reported that erythrocytes export intracellularly synthesized SIP into the extracellular space via an ATP-dependent transporter in a time-dependent manner without any

Abbreviations:  Em, emission wavelength; Ex, excitation wavelength; FTC, fumitremorgin C; DMF, dimethylformamide; NBD, 7-nitro-2,1,3-benzoxadiazol-4-yl; NBD-Sph, omega-(7-nitro-2,1,3-benzoxadiazol-4-yl) (2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol; SIP, sphingosine-1-phosphate.

To whom correspondence should be addressed.

*e-mail: tnishi@sanken.osaka-u.ac.jp

The online version of this article (available at http://www.jlr.org) contains a supplement.
extracellular stimuli (13). SPNS2 has been identified as an S1P transporter in vascular and lymphatic endothelial cells (14–17). A deficiency of SPNS2 in mice decreases the concentration of plasma S1P (14–16, 18) and impairs the egress of lymphocytes from the thymus (14–16, 18, 19). However, the S1P release from erythrocytes in SPNS2-deficient mice is normal (14). Therefore, SPNS2 is not an S1P transporter in erythrocytes, and another unknown transporter must fulfill this role in these cells.

Because the S1P transporter in erythrocytes plays an important role in the normal distribution of lymphocytes, its inhibitors are promising candidates for immunosuppressive drugs (20). To screen for compounds that inhibit the S1P transporter in erythrocytes, a rapid assay for measuring S1P export from erythrocytes is indispensable. Currently, S1P transport activity can be measured using radioactive S1P, followed by TLC or liquid scintillation counting (13) and HPLC to detect ortho-phthalaldehyde-labeled S1P (21) or LC/MS/MS to detect native S1P (14). These methods are unsuitable for high-throughput measurements of S1P transporter activity because they require many steps to detect S1P and are time consuming. Thus, we attempted to develop a simple assay of S1P transport by erythrocytes by using a fluorescent S1P analog of S1P, 7-nitro-2-1,3-benzoxadiazol-4-yl (NBD)-S1P.

MATERIALS AND METHODS

Materials

C17-S1P, NBD-sphingosine (NBD-Sph), NBD-S1P, sphingosine, and S1P were purchased from Avanti Polar Lipids (Alabaster, AL). BSA (fatty acid-free), glyburide, and cyclosporine A were obtained from Sigma-Aldrich (St. Louis, MO). MK571 was purchased from Calbiochem (San Diego, CA). Fumitremorgin C (FTC) was acquired from BioViotica (Dransfeld, Germany). Other reagents were of special grade and were obtained from Wako Chemicals (Osaka, Japan) or Nacalai Tesque (Kyoto, Japan). HPTLC Silica gel 60 plates were purchased from Merck (Darmstadt, Germany).

Preparation of rat erythrocytes

Female Wistar rats (10–15 weeks of age) were anesthetized and approximately 300 µl of blood was collected from the tail vein using an acid citrate-dextrose solution as an anticoagulant. Erythrocytes were prepared by centrifugation at 500 g for 15 min, washed twice with buffer A [20 mM HEPES-NaOH (pH 7.4), 3.3 mM NaH2PO4, 2.9 mM KCl, 1 mM MgCl2, 138 mM NaCl, and 1 g/l glucose] containing 1% BSA, and resuspended in the same buffer. For the preparation of erythrocytes suspended in a buffer containing 0.1% BSA, erythrocytes were washed twice with buffer A containing 1% BSA and then once with buffer A containing 0.1% BSA. All experimental procedures using rats were conducted in conformity with the Public Health Service Policy on the Humane Care and Use of Laboratory Animals and followed the regulations of the Institutional Animal Care and Use Committee of the Faculty of Pharmaceutical Sciences, Setsunan University (approval number: K15-32, K16-6).

Quantification of NBD-S1P and S1P release from rat erythrocytes

First, 100 µl of erythrocyte suspension (1 × 10^7 cells) in assay buffer and 100 µl of assay buffer containing 10 µM NBD-Sph were preincubated at 37°C for 10 min. Then, the erythrocytes and the buffer containing NBD-Sph were mixed (final NBD-Sph concentration: 5 µM) and incubated at 37°C. After incubation, the erythrocytes and assay buffer were separated by centrifugation for 5 s at 17,000 g. For the TLC assay, lipids were extracted from the assay buffer and erythrocytes under acidic conditions by using the modified Bligh-Dyer method and were developed as described by Yamori et al. (22) (Fig. 1A, left). The fluorescent bands of NBD-labeled lipids were quantified using ImageQuant LAS 4000 mini (GE Healthcare Japan, Tokyo, Japan) or ChemiDoc MP (Bio-Rad, Hercules, CA). To quantify the amount of NBD-S1P using a 96-well plate reader or the amount of S1P using HPLC, lipids were extracted from the assay buffer and erythrocytes under alkaline conditions using a modified protocol of Hisano et al. (21) (Fig. 1A right). Lipids were extracted from 200 µl of the assay buffer or lysed erythrocytes. Then, 260 µl of methanol and 400 µl of chloroform/methanol (1:1) were added to the samples and thoroughly mixed. Subsequently, 16 µl of 7 M NH4OH, 400 µl of chloroform, and 300 µl of 1.5 M KCl (or distilled water) were
added to the samples and mixed thoroughly. The lipids were separated by centrifugation for 5 min at 17,000 g. The fluorescence intensities of the upper aqueous phases containing NBD-S1P were measured at 530/538 nm with excitation at 490/485 nm in 96-well plates using MTP-810Lab (Corona Electric, Ibaraki, Japan) or FMAX (Molecular Devices, Sunnyvale, CA) (Fig. 1A, right). To quantify NBD-S1P, an aliquot of the upper phase was dried, redissolved in 20 µl of chloroform/methanol (2:1), and analyzed by TLC (Fig. 1A, middle). To quantify S1P by HPLC, the upper aqueous phases were treated with alkaline phosphatases and modified using o-phthalaldehyde, as described by Hisano et al. (21).

RESULTS

NBD-S1P is an S1P transporter substrate in rat erythrocytes

We previously demonstrated that the substrate recognition of erythrocyte S1P transporters is restricted because their activity is not inhibited by DH-S1P or ceramide-1-phosphate (13). Thus, we examined whether NBD-S1P is exported by the S1P transporter of erythrocytes. When NBD-Sph was added to erythrocytes, it was slowly incorporated into the erythrocytes and readily phosphorylated to NBD-S1P (Fig. 1B), as reported previously for Chinese hamster ovary (CHO) cells (23). Synthesized NBD-S1P was immediately exported to the extracellular buffer at a linear rate for at least 2 h (Fig. 1C, supplemental Fig. S1). The kinetic profile of NBD-S1P release is similar to that of S1P release in erythrocytes (13). We previously demonstrated that the erythrocyte S1P transporter is sensitive to an ABC transporter inhibitor, glyburide (13). Similarly, NBD-S1P release from erythrocytes was inhibited by glyburide, but not by MK571, cyclosporine A, or FTC; these compounds are known inhibitors of ABCA1, ABCG1, and ABCG2, respectively (Fig. 2). Glyburide clearly inhibited the transport of NBD-S1P, but not the phosphorylation of NBD-Sph, because NBD-S1P accumulated intracellularly when glyburide was added to the assay buffer (Fig. 2A). Furthermore, we investigated the competitive inhibition of NBD-S1P and S1P transport in erythrocytes by S1P and NBD-S1P, respectively (Fig. 3; supplemental Figs. S2, S3). When the same concentrations of NBD-Sph and sphingosine were added to erythrocytes simultaneously, the phosphorylation of NBD-Sph decreased (supplemental Fig. S4). Thus, erythrocytes were preincubated with NBD-Sph for 1 h and then incubated in the presence or absence of sphingosine (Fig. 3A, supplemental Fig. S2). When sphingosine was added to the erythrocytes, it readily incorporated into the cells and converted to S1P (supplemental Fig. S2B). In the presence of sphingosine, NBD-S1P transport decreased in accordance with the amount of intracellular S1P (Fig. 3A, supplemental Fig. S2B). We also investigated the effect of intracellular NBD-S1P on the S1P transport in erythrocytes (Fig. 3B, supplemental Fig. S3). When 10- or 50-fold NBD-Sph was added to erythrocytes with sphingosine, the amount of intracellular NBD-S1P increased (supplemental Fig. S3A), and S1P transport was suppressed, in accordance with the amount of intracellular NBD-S1P (Fig. 3B, supplemental Fig. S3A). These results indicate that S1P and NBD-S1P share the same transport system in erythrocytes.

Optimization of a fluorescence-based S1P transport assay

To evaluate the reliability of NBD-S1P as a fluorescence-based indicator of S1P transport activity in erythrocytes, the fluorescence intensity and amount of exported NBD-S1P were compared under different transport assay buffer or lipid extraction conditions (Figs. 4, 5). To establish the most sensitive assay conditions for detecting the amount of exported NBD-S1P using a microplate fluorometer, NBD-Sph was separated from the transport assay buffer by...
chloroform/methanol extraction, and an aqueous phase containing NBD-S1P was used as described in the Materials and Methods. For the S1P transport assay, we typically utilized a transport assay buffer containing 1% BSA that is used for the S1P carrier protein and stabilizes the erythrocyte membrane (13). When the assay buffer contained no or 0.01% BSA, the erythrocytes were slightly lysed (data not shown). Thus, we compared the amounts of exported NBD-S1P in assay buffers containing 0.1 and 1% BSA after 1 h of incubation with NBD-Sph (Fig. 4A, B). The fluorescence intensity of the aqueous phase containing NBD-S1P that was extracted from the 1% BSA-containing buffer was higher than that obtained from 0.1% BSA-containing buffer at each time point (Fig. 4A). However, the amounts of NBD-S1P did not differ between the assay buffers (Fig. 4B). Although 1% BSA enhanced the fluorescence intensity of NBD-S1P, it also increased the background fluorescence of the microplate assay. Thus, 0.1% BSA is suitable for quantifying NBD-S1P transport in a microplate assay. KCl is typically used for lipid extraction, but chloride ions are known to attenuate fluorescence intensity. Therefore, we investigated the effect of KCl on the lipid extraction (Fig. 4C, D). When KCl was not added during the lipid extraction procedure (as described in the Materials and Methods), the extracellular fluorescence intensity increased at 60 min, but not at 0.5 min (Fig. 4C); whereas, the amount of extracellular NBD-S1P decreased slightly (Fig. 4D). Thus, KCl could be omitted from the lipid extraction method by replacing the KCl solution with the same volume of distilled water. We also reduced the volumes of methanol and distilled water used in the lipid extraction to increase the NBD-S1P concentration of the resulting upper phase (Fig. 5A, B). Adding 200 µl of methanol, but no water, produced the highest extracellular fluorescence after a 60 min incubation with less contamination of NBD-Sph in the aqueous phase (the measurement obtained at 0.5 min was used as the background, Fig. 5A, B). The high background fluorescence observed in several samples after incubation for 0.5 min is attributable to NBD-Sph contamination in the aqueous phase, as confirmed by TLC analysis (Fig. 5B). Finally, we investigated the effect of dimethylformamide (DMF), which was reported to increase the fluorescence intensity of 15-NBD-S1P (24) on the fluorescence intensity of exported NBD-S1P in the assay buffer (Fig. 5C). The fluorescence intensity of the aqueous phase containing NBD-S1P increased at 60 min, but not at 0.5 min (Fig. 5C).
Based on these results, the optimized conditions for the NBD-S1P transport assay were defined as follows: After incubating erythrocytes with NBD-Sph in 200 μl of buffer A containing 0.1% BSA, lipid extraction should be performed by stepwise addition of 400 μl of chloroform/methanol (1:1), 16 μl of 7 M NH₄OH, and 400 μl of chloroform; 160 μl of aqueous phase with 40 μl of DMF should be used for fluorescence detection.

**Quantification of NBD-S1P release using a microplate reader**

To quantify the amounts of extracellular and intracellular NBD-S1P, standard curves were generated (supplemental Fig. S5). Known concentrations of NBD-S1P were added to the assay buffer or erythrocyte lysate and extracted, and then, the fluorescence of NBD-S1P was measured as described above. Because erythrocyte lysates affect the intensity of NBD-S1P fluorescence, separate standard curves for extracellular and intracellular NBD-S1P were made (supplemental Fig. S5). Because half of the aqueous phase was sufficient to determine NBD-S1P release, the volumes of the samples and reagents optimized in the previous section were reduced by half. Intracellular NBD-S1P increased and reached a maximum (600 pmol/10⁷ cells) at 30 min (supplemental Fig. S6). In contrast, the amount of exported NBD-S1P increased linearly until 60 min (Fig. 6A). These results are consistent with the TLC findings (supplemental Fig. S1).

The intensity of NBD-S1P increased as the ratio of DMF to aqueous phase increased and peaked at a ratio of 160:40 (aqueous phase:DMF) (Fig. 5C). When the aqueous phase was prepared from assay buffer containing 1% BSA, the addition of DMF created white precipitate more frequently than when assay buffer containing 0.1% BSA was used.
In our conventional method, 1% BSA is used to promote the efficient export of S1P. However, 1% BSA trapped more NBD-Sph in the extracellular medium and made distinguishing the fluorescence of NBD-S1P and NBD-Sph in the assay buffer difficult (Fig. 1C). As shown in Fig. 1C, the amount of extracellular NBD-Sph was much lower in 0.1% BSA than in 1% BSA. Therefore, we investigated whether the fluorescence increase of NBD-S1P in extracellular assay buffer containing 0.1% BSA could be detected without lipid extraction (Fig. 6B). The fluorescence increase caused by the extracellular assay buffer was observed clearly after 120 min of incubation. Thus, NBD-S1P release can be detected in the assay buffer without the influence of NBD-Sph by directly measuring the fluorescence of the assay buffer without lipid extraction.

**DISCUSSION**

In erythrocytes, sphingosine is incorporated into cells and converted to S1P because of sphingosine kinase activity and the lack of ceramide synthase activity (6). Similarly, NBD-Sph is also only converted to its phosphorylated form, NBD-S1P, in erythrocytes (Fig. 1B, C). In CHO cells, NBD-Sph is incorporated into the cells and converted into several NBD-labeled sphingolipids, including NBD-S1P, NBD-ceramide, and NBD-sphingomyelin, similarly to sphingosine metabolism (23). The simplicity of sphingosine metabolism in erythrocytes facilitates interpreting changes in the fluorescence intensity derived from NBD-S1P; thus, changes in the amount of NBD-S1P were determined in terms of NBD-S1P transport and/or sphingosine kinase activity.

Previously, we showed that sphingosine is readily incorporated into erythrocytes and phosphorylated to S1P (13). The sphingosine kinase activity in erythrocytes was extremely limited (3 pmol/min/mg) (7), but the abundance of erythrocytes in blood enables a high concentration of S1P in plasma. When NBD-Sph was added to erythrocytes, the amount of intracellular NBD-Sph was much smaller than that of extracellular NBD-Sph (Fig. 1B, C). In contrast to the results shown in Fig. 1B, C and supplemental Fig. S1, which were obtained using a higher concentration of NBD-Sph (5 μM) than of sphingosine (0.01 μM) (13), a lower rate of NBD-Sph incorporation was observed under the same conditions (0.01 μM NBD-Sph, supplemental Fig. S7). In addition, NBD-Sph was efficiently incorporated into erythrocytes when the BSA concentration was 0.1% than when it was 1% (Fig. 1B). These results suggest that the NBD moiety of NBD-Sph decreases the incorporation velocity of NBD-Sph across plasma membranes and/or causes NBD-Sph to prefer the extracellular medium by increasing its binding affinity for BSA.

In erythrocytes, S1P is produced only by sphingosine kinase 1 (25). Although NBD-Sph was readily converted to NBD-S1P following the incorporation of NBD-Sph into erythrocytes (Fig. 1B), the rate of NBD-Sph phosphorylation is estimated to be 20% of that of sphingosine (24, 26, 27). Consistent with this estimate, the addition of sphingosine to the extracellular buffer with NBD-Sph decreased the production of intracellular NBD-S1P without affecting the amount of intracellular NBD-Sph (supplemental Fig. S4). Therefore, sphingosine is a better substrate for sphingosine kinase 1 than NBD-Sph. Although more intracellular NBD-S1P was synthesized in the assay buffer containing 0.1% BSA than in that containing 1% BSA, similar amounts of NBD-S1P were released under both assay conditions (Fig. 1B, C). This finding is different from that observed with SPNS2, which exports S1P as a passive transporter depending on the intracellular S1P concentration (21). The saturation of NBD-S1P release suggests the involvement of an active transport system in S1P release from erythrocytes.

To date, SPNS2 is the only S1P transporter that has been identified (18). A defect in SPNS2 in mice caused a large decrease in circulating T cells and an accumulation of cells in the thymus, although the S1P concentration of the blood plasma was maintained at 60% of that in wild-type mice (14). The plasma S1P concentration in SPNS2-deficient mice is probably sufficient to generate the S1P concentration gradient between blood and lymphoid organs that has been suggested to be necessary for lymphocyte egress from the organs to blood. SPNS2-deficiency in mice impaired the S1P release from vascular endothelial cells, but not from erythrocytes. SPNS2 expression was detected in vascular endothelial cells of the thymus (14). Thus, we hypothesized that SPNS2 regulates lymphocyte trafficking by supplying local extracellular S1P surrounding the site of lymphocyte exit from the thymus (20). Erythrocytes are the major supplier of the plasma S1P necessary for normal lymphocyte trafficking. Because S1P release from erythrocytes in SPNS2-deficient mice is normal, another S1P transporter is expressed in erythrocytes and regulates the circulation of lymphocytes. These results suggested that different S1P transporters expressed in different cell types may make different individual contributions to lymphocyte trafficking. These features of S1P transporters will likely enable the discovery of immunosuppressive drugs targeted to these proteins, which will have individual pharmacological actions and limited side effects.

Recently, a high-throughput assay method for measuring sphingosine kinase activity by detecting NBD-S1P in a mixture containing NBD-Sph was reported (27). In this method, the addition of 0.05% Triton X-100 causes a red-shift in the fluorescence of NBD-S1P and enables the measurement of NBD-S1P in a mixture containing NBD-Sph. However, quantifying NBD-S1P at concentrations less than 1 μM is difficult using this method because approximately 1 μM NBD-S1P results in no fluorescence (Ex = 550 nm, Em = 584 nm). Actually, we could not detect the fluorescence (Ex = 550 nm, Em = 584 nm) of 1.25 μM NBD-S1P (Ex = 550 nm, Em = 584 nm) in buffer A with or without 0.1% BSA in the presence of 0.05% Triton X-100. Thus, using our experimental conditions, it is difficult to distinguish the fluorescence of NBD-S1P and NBD-Sph. However, as shown in Fig. 6B, we successfully detected the fluorescence increase in the extracellular assay buffer attributed to NBD-S1P release without lipid extraction by reducing the BSA concentration. Although determining the precise amount of released NBD-S1P is difficult because of the small amount of residual NBD-Sph in the assay buffer, this method is
useful for assaying many samples and, thus, likely has applications in high-throughput screening.

The characteristics of the methods used for this study and the previously reported methods used for measuring SIP release from cells are summarized in supplemental Table S1. Among the three methods used for detecting NBD-SIP transport, the TLC method provides better sensitivity, but requires more time for lipid extraction, separation, and detection. The two microplate reader methods require the shortest time for lipid extraction and detection, and the lowest costs for operation and equipment, whereas their sensitivities are lower than those of the TLC method. The exclusion of lipid separation from the microplate reader methods substantially shortens the required time. This method allows for the shortest running time for detecting SIP transport activity. The time required for lipid extraction, separation, and detection in the LC/MS/MS method is comparable to that of the plate reader methods and is shorter than the other methods, and can be completed within 30 min. SIP measurement using LC/MS/MS is very sensitive, but it requires approximately 14 min per sample for separation and detection, and a large initial investment for equipment is required, as well as a specialist to operate the instrument. Therefore, the LC/MS/MS method is not suitable for the high throughput screening of the drugs that target SIP transport activity in erythrocytes. The microplate reader methods developed in this study require only a very short time for detection and have a lower cost for operation and equipment than all other methods. Therefore, the microplate reader methods are the best choice for measuring SIP transport activity in erythrocytes regarding throughput, multiplexing, cost, and ease of use.

When the SIP concentration of blood plasma was drastically decreased, lymphocyte exit from lymphoid organs was suppressed (10). Because the erythrocyte SIP transporter controls the SIP concentration in the plasma, inhibition of the transporter likely decreases SIP levels in the plasma and suppresses lymphocyte exit from lymphoid organs. Therefore, SIP transporters are good targets for new immunosuppressive agents. In this study, we report a method for measuring erythrocyte SIP transport activity that is quicker than conventional methods. This method will facilitate screening for new immunosuppressive drugs that specifically target the erythrocyte SIP transporter. This is the first report of a fluorescence assay for measuring SIP transporter activity.

REFERENCES

1. Chi, H. 2011. Sphingosine-1-phosphate and immune regulation: trafficking and beyond. Trends Pharmacol. Sci. 32: 16–24.
2. Cyster, J. G., and S. R. Schwab. 2012. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu. Rev. Immunol. 30: 69–94.
3. Spiegel, S., and S. Müll von 2011. The outs and the ins of sphingosine-1-phosphate in immunity. Nat. Rev. Immunol. 11: 403–415.
4. Proia, R. L., and T. Hla. 2015. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J. Clin. Invest. 125: 1379–1387.
5. Rivera, J., R. L. Proia, and A. Olivera. 2008. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat. Rev. Immunol. 8: 753–763.
6. Yang, L., Y. Yatomi, Y. Miura, K. Satoh, and Y. Ozaki. 1999. Metabolism and functional effects of sphingolipids in blood cells. Br. J. Haematol. 107: 282–293.
7. Ito, K., Y. Anada, M. Tani, M. Ikeda, T. Sano, A. Kihara, and Y. Igarashi. 2007. Lack of sphingosine 1-phosphate-degrading enzymes in erythrocytes. Biochim. Biophys. Acta. 1768: 312–317.
8. Venkataraman, K., Y. M. Lee, J. Michaud, S. Thangada, Y. Ai, H. L. Bonkovsky, N. S. Parikh, C. Habruckovich, and T. Hla. 2008. Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ. Res. 102: 659–676.
9. Oliveira, A. M. L. Allende, and R. L. Proia. 2013. Shaping the landscape: metabolic regulation of SIP gradients. Biochim. Biophys. Acta. 1831: 193–202.
10. Pappu, R., S. R. Schwab, I. Cornelissen, J. P. Pereira, J. B. Regard, Y. Xu, E. Camerer, Y. W. Zheng, Y. Huang, J. G. Cyster, et al. 2007. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 316: 295–298.
11. Hanel, P., F. Andreini, and M. H. Gräler. 2007. Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J. 21: 1209–1209.
12. Xu, R., W. Sun, J. Jin, L. M. Obeid, and C. Mao. 2010. Role of alkaline ceramidases in the generation of sphingosine and its phosphate in erythrocytes. FASEB J. 24: 2507–2515.
13. Kobayashi, N., N. Kobayashi, A. Yamaguchi, and T. Nishi. 2009. Characterization of the ATP-dependent sphingosine 1-phosphate transporter in rat erythrocytes. J. Biol. Chem. 284: 21192–21200.
14. Hisano, Y., N. Kobayashi, A. Yamaguchi, and T. Nishi. 2012. Mouse SPNS2 functions as a sphingosine-1-phosphate transporter in vascular endothelial cells. PLoS One. 7:e38941.
15. Fukuhara, S., S. Simmons, S. Kawamura, A. Inoue, Y. Orba, T. Tokudome, Y. Sunden, Y. Arai, K. Moriwaki, J. Ishida, et al. 2012. The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J. Clin. Invest. 122: 1416–1426.
16. Nagahashi, M., E. Y. Kim, A. Yamada, S. Ramachandran, J. C. Allegood, N. C. Hau, M. Maceyka, S. Müll von, T. Takabe, and S. Spiegel. 2013. Spns2, a transporter of phosphorylated sphingolipid bases, regulates their blood and lymph levels, and the lymphatic network. FASEB J. 27: 1001–1011.
17. Mendoza, A., B. Breart, W. D. Ramos-Perez, L. A. Pitt, M. Gobert, M. Sunkara, J. J. Lafaille, A. J. Morris, and S. R. Schwab. 2012. The transporter Spns2 is required for secretion of lymph but not plasma sphingosine-1-phosphate. Cell Reports. 2: 1104–1110.
18. Hisano, Y., T. Nishi, and A. Kawahara. 2012. The functional roles of SIP in immunity. J. Biochem. 152: 305–311.
19. Nijjnik, A., S. Clare, C. Hale, J. Chen, C. Raisen, L. Mottram, M. Lucas, J. Estabel, E. Ryder, H. Adissu, et al. 2012. The role of sphingosine-1-phosphate transporter Spns2 in immune system function. J. Immunol. 189: 102–111.
20. Nishi, T., N. Kobayashi, and Y. Arai. 2014. Molecular and physiological functions of sphingosine 1-phosphate transporters. Biochim. Biophys. Acta. 1841: 759–765.
21. Hisano, Y., N. Kobayashi, A. Kawahara, and Y. Arai. 2011. The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720. J. Biol. Chem. 286: 1758–1766.
22. Yatomi, Y., T. Ohmori, G. Rile, F. Kazama, H. Okamoto, T. Sano, K. Satoh, S. Kume, G. Tighi, Y. Igarashi, et al. 2008. Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood. 96: 3431–3438.
23. Hakogi, T., T. Shigeno, S. Katsuman, T. Sano, T. Kohno, and Y. Igarashi. 2003. Synthesis of fluorescence-labeled sphingosine and sphingosine 1-phosphate; effective tools for sphingosine and sphingosine 1-phosphate behavior. Bioorg. Med. Chem. Lett. 13: 661–664.
24. Billich, A., and P. Ettmayer. 2004. Fluorescence-based assay of sphingosine kinases. Anal. Biochem. 326: 114–119.
25. Igarashi, A., and Y. Igarashi. 2008. Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720. Biochim. Biophys. Acta. 1781: 496–502.
26. Ettmayer, P., A. Billich, T. Baumruker, D. Mechtheriakova, H. Schmid, and P. Nussbauer. 2004. Fluorescence-labeled sphingosines as substrates of sphingosine kinases 1 and 2. Bioorg. Med. Chem. Lett. 14: 1555–1558.
27. Lima, S., S. Müll von, and S. Spiegel. 2014. A real-time high-throughput fluorescence assay for sphingosine kinases. J. Lipid Res. 55: 1525–1530.